CA2725972A1 - Paeoniflorin preparations and uses thereof for fat reduction - Google Patents

Paeoniflorin preparations and uses thereof for fat reduction Download PDF

Info

Publication number
CA2725972A1
CA2725972A1 CA2725972A CA2725972A CA2725972A1 CA 2725972 A1 CA2725972 A1 CA 2725972A1 CA 2725972 A CA2725972 A CA 2725972A CA 2725972 A CA2725972 A CA 2725972A CA 2725972 A1 CA2725972 A1 CA 2725972A1
Authority
CA
Canada
Prior art keywords
preparation
adipolysis
fat
paeoniflorin
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2725972A
Other languages
English (en)
French (fr)
Inventor
Bakr Rabie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2725972A1 publication Critical patent/CA2725972A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0452—Specially adapted for transcutaneous muscle stimulation [TMS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0008—Destruction of fat cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CA2725972A 2008-05-23 2009-05-25 Paeoniflorin preparations and uses thereof for fat reduction Abandoned CA2725972A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/126,246 US7943187B2 (en) 2008-05-23 2008-05-23 Paeoniflorin preparations and uses thereof for fat reduction
US12/126,246 2008-05-23
PCT/CN2009/000569 WO2010127470A1 (en) 2008-05-23 2009-05-25 Paeoniflorin preparations and uses thereof for fat reduction

Publications (1)

Publication Number Publication Date
CA2725972A1 true CA2725972A1 (en) 2010-11-11

Family

ID=41342622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2725972A Abandoned CA2725972A1 (en) 2008-05-23 2009-05-25 Paeoniflorin preparations and uses thereof for fat reduction

Country Status (9)

Country Link
US (4) US7943187B2 (OSRAM)
EP (1) EP2300018B1 (OSRAM)
JP (1) JP5507549B2 (OSRAM)
KR (1) KR101656536B1 (OSRAM)
CN (1) CN102170888B (OSRAM)
AU (2) AU2009345773A1 (OSRAM)
CA (1) CA2725972A1 (OSRAM)
DK (1) DK2300018T3 (OSRAM)
WO (1) WO2010127470A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20130012840A1 (en) * 2010-03-23 2013-01-10 Real Aesthetics Ltd. System and method for accelerating the relative proportion of fat catabolism
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
WO2015061280A1 (en) 2013-10-21 2015-04-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2017079700A1 (en) * 2015-11-04 2017-05-11 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
WO2019156213A1 (ja) 2018-02-09 2019-08-15 琥珀バイオテクノロジー株式会社 グリセロール放出促進剤
KR102392292B1 (ko) 2021-07-21 2022-05-03 중앙대학교 산학협력단 페오니플로린을 포함하는 악액질 및 근손실 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485990A (en) * 1987-09-28 1989-03-30 Tsumura & Co Antihypertestoeronemia agent
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5919621A (en) 1991-10-24 1999-07-06 Brown; David B. Methods for diagnosing human male infertility
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5480772A (en) 1993-02-03 1996-01-02 Brandeis University In vitro activation of a nucleus
FR2717382B1 (fr) * 1994-03-21 1996-06-07 Fabre Pierre Cosmetique Extraits de Paeonia Lactiflora titré en paeoniflorine utiles en cosmétologie dans le traitement capillaire.
PE17897A1 (es) * 1995-02-17 1997-06-12 Lilly Co Eli Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
US5698199A (en) * 1995-03-10 1997-12-16 Kao Corporation Lipolysis acceleration method
EP1021191B1 (de) 1997-10-08 2002-06-05 Genesiscosmetics Rights & Licenses Company Limited Straffung und/oder verkleinerung von fettzellen-haltigen körperpartien
US6638064B1 (en) * 2000-06-07 2003-10-28 Robert Scott Nance Flexible endodontic syringe
ES2333849T3 (es) * 2001-04-20 2010-03-02 Alza Corporation Disposicion de microsalientes que presenta un revestimiento que contiene un agente beneficioso.
CN2560367Y (zh) * 2001-08-30 2003-07-16 夏勤 适于喉部和气管滴入药物的针头
US20030175328A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin
JP2004217583A (ja) * 2003-01-16 2004-08-05 Naris Cosmetics Co Ltd 痩身用皮膚外用剤
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
CN1555806A (zh) * 2003-12-31 2004-12-22 昆明同持医药研究有限公司 一种芍药甙注射剂及其制备方法和应用
US20080194496A1 (en) * 2004-05-10 2008-08-14 Lg Household & Health Care Ltd. Skin Aging Treatment Comprising Paeoniflorin
KR100769580B1 (ko) * 2005-03-07 2007-10-23 주식회사 엘지생활건강 자외선에 의한 피부 ｄｎａ 손상 방지제
KR20050107649A (ko) * 2004-05-10 2005-11-15 주식회사 엘지생활건강 페오니플로린을 포함하는 피부 노화 억제용 조성물
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US7530958B2 (en) * 2004-09-24 2009-05-12 Guided Therapy Systems, Inc. Method and system for combined ultrasound treatment
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
US20080294072A1 (en) * 2007-05-24 2008-11-27 Crutchfield Dermatology Mesotherapy with ultrasound
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction

Also Published As

Publication number Publication date
US20150018906A1 (en) 2015-01-15
CN102170888A (zh) 2011-08-31
US20090292238A1 (en) 2009-11-26
US20170368086A9 (en) 2017-12-28
KR20110138322A (ko) 2011-12-27
WO2010127470A1 (en) 2010-11-11
EP2300018B1 (en) 2017-05-17
EP2300018A1 (en) 2011-03-30
CN102170888B (zh) 2013-06-19
DK2300018T3 (en) 2017-09-11
US20110218163A1 (en) 2011-09-08
AU2015242976A1 (en) 2015-11-05
KR101656536B1 (ko) 2016-09-12
US8491947B2 (en) 2013-07-23
JP5507549B2 (ja) 2014-05-28
AU2009345773A1 (en) 2010-11-11
US9901591B2 (en) 2018-02-27
JP2011523950A (ja) 2011-08-25
US20170216333A1 (en) 2017-08-03
US7943187B2 (en) 2011-05-17
EP2300018A4 (en) 2011-07-20
HK1159477A1 (en) 2012-08-03

Similar Documents

Publication Publication Date Title
US9901591B2 (en) Paeoniflorin preparations and uses thereof for fat reduction
TW201803561A (zh) 軟性抗膽鹼類似物之製劑
CA2923064C (en) Transdermal composition for treating pain
JP2018516934A (ja) 脂肪量を低減するためのβ−ヒドロキシ−β−メチルブチレート（ＨＭＢ）の組成物および使用方法
Matarasso et al. Mesotherapy and injection lipolysis
WO2012071027A2 (en) Nutraceutical based topical anxiolytic agent and method of use
CN102580087B (zh) 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
Liao et al. Evaluation of ultrasound combined with chitosan for the control of weight and local fat in mice
Neziri et al. Effect of intravenous tropisetron on modulation of pain and central hypersensitivity in chronic low back pain patients
Barbosa et al. Body harmonization: The definition of a new concept
HK1159477B (en) Paeoniflorin preparations and uses thereof for fat reduction
Upadhyaya et al. Role of an indigenous drug Geriforte on blood levels of biogenic amines and its significance in the treatment of anxiety neurosis
US20070042998A1 (en) Medical cosmetic method for reducing adipose tissue and for initiating lipolysis through subcutaneous and intracutaneous injections and customized composition compounded from pharmaceutical agents for use therein
KR102230271B1 (ko) 지방감소를 위한 글라이코데옥시콜릭산 (Glycodeoxycholic acid, GDCA)를 유효성분으로 포함하는 주사용 제제 및 조성물
CN111093704A (zh) 用于减少身体脂肪的前列环素受体激动剂
Greenway et al. Anthropometry of local fat reduction
Abbasi et al. Transdermal delivery of metformin using microneedle and iontophoresis for combating obesity
BERBECE et al. Use of Phosphatidylcholine in the Treatment of Localized Fat Deposits
Braun Lipodissolve for body sculpting
CN119564656A (zh) 抗炎物质及其应用
Stob Post exercise protein feeding does not alter molecular markers of translation initiation or measures of skeletal muscle function
Beilin Body mesotherapy and ‘mesobotox’
CN113116826A (zh) 一种局部外用的卡马西平纳米制剂及其制备方法
Parada et al. Is dopamine (DA) in the lateral hypothalamus (LH) involved in the inhibitory regulation of exploratory behavior related to food and water seeking?
Beilin 31 Body mesotherapy and

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140207

FZDE Dead

Effective date: 20160727